Medicaid Pharmacy and Therapeutics Committee Agenda for February 20, 2008
The Pharmacy & Therapeutics Committee will meet February 20, 2008, from 9:00 a.m. to 3:30 p.m., Meeting Room 2, Concourse, Empire State Plaza, Albany, New York.
Review of the drugs for inclusion to the Clinical Drug Review Program (CDRP).
Description: The Committee will consider requiring prior authorization for the following drugs in order to address appropriate utilization consistent with approved indications including factors associated with long-term efficacy, public health, and potential for overuse or misuse.
- lidocaine patch (Lidoderm®)
- palivizumab (Synagis®)
- exenatide (Byetta®)
- fentanyl lozenge (Actiq®)
- fentanyl buccal tablet (Fentora®)
- dronabinol (Marinol®)
- nabilone (Cesamet®)
Agenda Timeline (subject to change based on meeting proceedings)
|9:00 - 9:15||Welcome and Introductions|
|9:15 - 10:15||Public Comments from interested parties *|
|10:15 - 10:30||Break|
|10:30 - 11:00||Review of lidocaine patch|
|11:00 - 11:30||Review of palivizumab|
|11:30 - 12:00||Review of exenatide|
|12:00 - 1:00||Lunch Break|
|1:00 - 1:30||Review of fentanyl (lozenge and buccal tablet)|
|1:30 - 2:00||Review of dronabinol and nabilone|
|2:00 - 2:45||Break|
|2:45 - 3:15||Summary of Recommendations|
|3:15 - 3:30||DOH Update, Final Comments and Adjournment|
* Interested parties must notify DOH at least 1 week in advance of their request to speak during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing email@example.com (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. All written comments regarding topics before the Committee must be received at least 1 week in advance of the meeting. Written comments should summarize key points and may not exceed two (2) pages in length.
NOTE: Those wishing to submit clinical studies or clinical reports, rather than comments, must submit the study/report at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material.
Posted January 18, 2008